BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month High on Analyst Upgrade

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) reached a new 52-week high during trading on Tuesday after Barclays raised their price target on the stock from $8.00 to $11.00. Barclays currently has an equal weight rating on the stock. BioCryst Pharmaceuticals traded as high as $11.11 and last traded at $11.03, with a volume of 24800859 shares trading hands. The stock had previously closed at $8.93.

Other analysts have also recently issued research reports about the stock. StockNews.com raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Evercore ISI increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Finally, Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $16.56.

Institutional Trading of BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after buying an additional 1,583,826 shares during the last quarter. Caligan Partners LP grew its holdings in shares of BioCryst Pharmaceuticals by 16.0% in the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after purchasing an additional 412,347 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of BioCryst Pharmaceuticals by 14.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock worth $18,799,000 after purchasing an additional 318,800 shares during the last quarter. Jupiter Asset Management Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after purchasing an additional 971,040 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of BioCryst Pharmaceuticals by 7.7% in the 4th quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock worth $15,077,000 after purchasing an additional 143,986 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Trading Up 0.6%

The business's fifty day simple moving average is $7.87 and its 200 day simple moving average is $7.89. The stock has a market cap of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. The firm's revenue was up 40.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.28 earnings per share. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.